PKM and metabolic dysfunction-associated steatohepatitis: hAnxA5 targeting PKM2 results in glycolysis inhibition and mitochondrial oxidative metabolism activation, triggering macrophage phenotype shift, and offers a novel therapeutic approach for NASH [83].